Proteomic Analysis of the Aqueous Humor in Age-related Macular Degeneration (AMD) Patients
详细信息 查看全文
- 作者：Tae Wan Kim ; Jeong Won Kang ; Jeeyun Ahn ; Eun Kyung Lee ; Kyung-Cho Cho ; Bit Na Ra Han ; Nam Young Hong ; Jisook Park ; Kwang Pyo Kim
- 刊名：Journal of Proteome Research
- 出版年：2012
- 出版时间：August 3, 2012
- 年：2012
- 卷：11
- 期：8
- 页码：4034-4043
- 全文大小：359K
- 年卷期：v.11,no.8(August 3, 2012)
- ISSN：1535-3907
文摘
Age-related macular degeneration (AMD) can lead to irreversible central vision loss in the elderly. Although large number of growth factor pathways, including the vascular endothelial growth factor (VEGF), has been implicated in the pathogenesis of AMD, no study has directly assessed the whole proteomic composition in the aqueous humor (AH) among AMD patients. The AH contains proteins secreted from the anterior segment tissue, and these proteins may play an important role in the pathogenesis of AMD. Thus, comparisons between the AH proteomic profiles of AMD patients and non-AMD controls may lead to the verification of novel pathogenic proteins useful as potential clinical biomarkers. In this study, we used discovery-based proteomics and Multiple Reaction Monitoring Mass Spectrometry (MRM-MS) to analyze AH from AMD patients and AH from controls who underwent cataract surgery. A total of 154 proteins with at least two unique peptides were identified in the AH. Of these 154 proteins identified by discovery-based proteomics, 10 AH proteins were novel identifications. The protein composition in the AH was different between AMD patients and non-AMD controls. Subsequently, a systematic MRM-MS assay was performed in seven highly abundant differentially expressed proteins from these groups. Differential expression of three proteins was observed in the AH of AMD patients compared with that of cataract controls (p < 0.0312). Elucidation of the aqueous proteome will establish a foundation for protein function analysis and identify differentially expressed markers associated with AMD. This study demonstrates that integrated proteomic technologies can yield novel biomarkers to detect exudative AMD.